Telomir Pharmaceuticals (NASDAQ:TELO) Trading 1.4% Higher – Here’s What Happened

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) shares traded up 1.4% during trading on Friday . The company traded as high as $1.4399 and last traded at $1.40. 59,205 shares were traded during mid-day trading, a decline of 33% from the average session volume of 88,933 shares. The stock had previously closed at $1.38.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Rodman & Renshaw assumed coverage on shares of Telomir Pharmaceuticals in a research report on Tuesday, January 13th. They issued a “buy” rating for the company. Wall Street Zen upgraded Telomir Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. Zacks Research upgraded Telomir Pharmaceuticals to a “hold” rating in a research note on Wednesday, March 18th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research note on Tuesday. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold”.

Telomir Pharmaceuticals Stock Performance

The firm has a market cap of $48.13 million, a P/E ratio of -4.24 and a beta of -0.73. The firm’s fifty day moving average is $1.29 and its 200 day moving average is $1.36.

Telomir Pharmaceuticals (NASDAQ:TELO) last announced its earnings results on Tuesday, March 17th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01.

Institutional Trading of Telomir Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. OneDigital Investment Advisors LLC boosted its stake in Telomir Pharmaceuticals by 64.3% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 23,000 shares of the company’s stock valued at $32,000 after purchasing an additional 9,000 shares during the period. Bank of America Corp DE boosted its stake in Telomir Pharmaceuticals by 283.9% in the 4th quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock valued at $61,000 after purchasing an additional 10,880 shares during the period. Qube Research & Technologies Ltd bought a new stake in Telomir Pharmaceuticals in the 2nd quarter valued at $33,000. Geode Capital Management LLC boosted its stake in Telomir Pharmaceuticals by 14.0% in the 4th quarter. Geode Capital Management LLC now owns 223,549 shares of the company’s stock valued at $297,000 after purchasing an additional 27,519 shares during the period. Finally, World Investment Advisors bought a new stake in Telomir Pharmaceuticals in the 4th quarter valued at $47,000.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.